Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$145.31
0.620.43%
al cierre: -
$145.31
0.000.00%
After hour: 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Biogen Inc ha un obiettivo di prezzo di consenso pari a $200.12, stabilito in base alle ultime valutazioni degli analisti di 30. Le ultime 3 valutazioni degli analisti sono state rilasciate da Morgan Stanley, Jefferies y Piper Sandler il octubre 10, 2025, septiembre 25, 2025 y agosto 14, 2025. Con un obiettivo di prezzo medio di $152.33 tra le Morgan Stanley, Jefferies y Piper Sandler, c'è un implicito 4.83% upside per Biogen Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Morgan Stanley
Jefferies
Piper Sandler
Citigroup
RBC Capital
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Biogen
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/10/2025 | 2.54% | Morgan Stanley | $144 → $149 | Maintains | Equal-Weight | |||
09/25/2025 | 30.75% | Jefferies | → $190 | Initiates | → Buy | |||
09/24/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
09/04/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
08/14/2025 | -18.79% | Piper Sandler | $115 → $118 | Maintains | Neutral | |||
08/01/2025 | -7.1% | Citigroup | $125 → $135 | Maintains | Neutral | |||
08/01/2025 | 50.71% | RBC Capital | $208 → $219 | Maintains | Outperform | |||
08/01/2025 | -0.9% | Morgan Stanley | $146 → $144 | Maintains | Equal-Weight | |||
08/01/2025 | 33.51% | HC Wainwright & Co. | $187 → $194 | Maintains | Buy | |||
07/07/2025 | 43.14% | RBC Capital | $213 → $208 | Maintains | Outperform | |||
06/27/2025 | 46.58% | RBC Capital | $213 → $213 | Reiterates | Outperform → Outperform | |||
06/26/2025 | 28.69% | HC Wainwright & Co. | $187 → $187 | Reiterates | Buy → Buy | |||
06/25/2025 | 46.58% | RBC Capital | $205 → $213 | Maintains | Outperform | |||
06/12/2025 | -20.86% | Piper Sandler | $115 → $115 | Reiterates | Neutral → Neutral | |||
06/12/2025 | -16.73% | Wedbush | $121 → $121 | Reiterates | Neutral → Neutral | |||
06/12/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
05/07/2025 | 16.3% | Mizuho | $207 → $169 | Maintains | Outperform | |||
05/05/2025 | 20.43% | JP Morgan | $185 → $175 | Maintains | Neutral | |||
05/02/2025 | 41.08% | RBC Capital | $217 → $205 | Maintains | Outperform | |||
05/02/2025 | 51.4% | Canaccord Genuity | $265 → $220 | Maintains | Buy | |||
05/02/2025 | 28.69% | HC Wainwright & Co. | $241 → $187 | Maintains | Buy | |||
05/02/2025 | 75.49% | Baird | $300 → $255 | Maintains | Outperform | |||
05/02/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
04/29/2025 | 36.95% | Truist Securities | $210 → $199 | Maintains | Buy | |||
04/29/2025 | -20.86% | Piper Sandler | $135 → $115 | Maintains | Neutral | |||
04/25/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
04/23/2025 | 35.57% | Goldman Sachs | $219 → $197 | Maintains | Buy | |||
04/22/2025 | 54.84% | RBC Capital | $221 → $225 | Maintains | Outperform | |||
04/16/2025 | -16.73% | Wedbush | $135 → $121 | Maintains | Neutral | |||
04/16/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
04/09/2025 | 4.6% | Morgan Stanley | $157 → $152 | Maintains | Equal-Weight | |||
04/04/2025 | — | Argus Research | — | Downgrade | Buy → Hold | |||
02/18/2025 | -7.1% | Piper Sandler | $138 → $135 | Reiterates | Neutral → Neutral | |||
02/13/2025 | 54.15% | Scotiabank | $244 → $224 | Maintains | Sector Outperform | |||
02/13/2025 | -4.34% | BMO Capital | $156 → $139 | Maintains | Market Perform | |||
02/13/2025 | 8.04% | Morgan Stanley | $192 → $157 | Maintains | Equal-Weight | |||
02/13/2025 | 68.61% | Goldman Sachs | $281 → $245 | Maintains | Buy | |||
02/13/2025 | 54.84% | RBC Capital | $231 → $225 | Maintains | Outperform | |||
02/13/2025 | -0.21% | Citigroup | $160 → $145 | Maintains | Neutral | |||
02/13/2025 | -3.65% | Wells Fargo | $165 → $140 | Maintains | Equal-Weight | |||
02/13/2025 | 65.85% | HC Wainwright & Co. | $300 → $241 | Maintains | Buy | |||
02/13/2025 | 44.52% | Truist Securities | $220 → $210 | Maintains | Buy | |||
02/13/2025 | 82.37% | Canaccord Genuity | $298 → $265 | Maintains | Buy | |||
02/13/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
01/29/2025 | 7.36% | BMO Capital | $164 → $156 | Maintains | Market Perform | |||
01/28/2025 | 10.11% | Citigroup | $190 → $160 | Maintains | Neutral | |||
01/10/2025 | 13.55% | Wells Fargo | $190 → $165 | Maintains | Equal-Weight | |||
01/08/2025 | 51.4% | Truist Securities | $302 → $220 | Maintains | Buy | |||
01/02/2025 | -5.03% | Piper Sandler | $315 → $138 | Downgrade | Overweight → Neutral | |||
12/20/2024 | 12.86% | BMO Capital | $230 → $164 | Downgrade | Outperform → Market Perform | |||
12/10/2024 | 22.5% | B of A Securities | → $178 | Reinstates | → Neutral | |||
12/09/2024 | 23.87% | Jefferies | $250 → $180 | Downgrade | Buy → Hold | |||
12/05/2024 | 32.13% | Morgan Stanley | $204 → $192 | Maintains | Equal-Weight | |||
11/21/2024 | 42.45% | Mizuho | $251 → $207 | Maintains | Outperform | |||
11/18/2024 | 85.81% | Needham | $270 → $270 | Downgrade | Buy → Hold | |||
11/15/2024 | 106.46% | Baird | $294 → $300 | Maintains | Outperform | |||
11/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/14/2024 | 30.75% | Citigroup | → $190 | Initiates | → Neutral | |||
11/04/2024 | 44.52% | JP Morgan | $220 → $210 | Maintains | Neutral | |||
10/31/2024 | 30.75% | Wells Fargo | $225 → $190 | Maintains | Equal-Weight | |||
10/31/2024 | 75.49% | Oppenheimer | $270 → $255 | Maintains | Outperform | |||
10/31/2024 | 23.87% | Barclays | $190 → $180 | Maintains | Equal-Weight | |||
10/31/2024 | 89.25% | TD Cowen | $300 → $275 | Maintains | Buy | |||
10/31/2024 | 106.46% | HC Wainwright & Co. | $300 → $300 | Reiterates | Buy → Buy | |||
10/31/2024 | 85.81% | Needham | $270 → $270 | Reiterates | Buy → Buy | |||
10/31/2024 | 40.39% | Morgan Stanley | $285 → $204 | Downgrade | Overweight → Equal-Weight | |||
10/30/2024 | 85.81% | Needham | $270 → $270 | Reiterates | Buy → Buy | |||
10/17/2024 | 58.28% | BMO Capital | $260 → $230 | Maintains | Outperform | |||
10/10/2024 | — | Raymond James | — | Reinstates | → Market Perform | |||
10/04/2024 | 85.12% | RBC Capital | $292 → $269 | Maintains | Outperform | |||
10/03/2024 | 39.01% | UBS | $234 → $202 | Maintains | Neutral | |||
09/24/2024 | 96.13% | Needham | $285 → $285 | Reiterates | Buy → Buy | |||
09/23/2024 | 41.08% | Wedbush | $210 → $205 | Maintains | Neutral | |||
09/19/2024 | 100.95% | RBC Capital | $292 → $292 | Reiterates | Outperform → Outperform | |||
09/09/2024 | 100.95% | Cantor Fitzgerald | $292 → $292 | Reiterates | Overweight → Overweight | |||
09/04/2024 | 96.13% | Needham | $285 → $285 | Reiterates | Buy → Buy | |||
08/19/2024 | 96.13% | Needham | $285 → $285 | Reiterates | Buy → Buy | |||
08/06/2024 | 72.73% | Mizuho | $277 → $251 | Maintains | Outperform | |||
08/05/2024 | 107.83% | Truist Securities | $340 → $302 | Reiterates | Buy → Buy | |||
08/05/2024 | 96.13% | Needham | $288 → $285 | Maintains | Buy | |||
08/02/2024 | 100.95% | RBC Capital | $282 → $292 | Maintains | Outperform | |||
08/02/2024 | 54.84% | Wells Fargo | $240 → $225 | Maintains | Equal-Weight | |||
08/02/2024 | 67.92% | Scotiabank | $275 → $244 | Maintains | Sector Outperform | |||
08/02/2024 | 30.75% | Barclays | $200 → $190 | Maintains | Equal-Weight | |||
08/02/2024 | 44.52% | Wedbush | $215 → $210 | Maintains | Neutral | |||
08/01/2024 | 98.2% | Needham | $288 → $288 | Reiterates | Buy → Buy | |||
07/29/2024 | 102.33% | Baird | $316 → $294 | Maintains | Outperform | |||
07/26/2024 | 102.33% | Needham | $294 → $294 | Reiterates | Buy → Buy | |||
07/12/2024 | 115.4% | Piper Sandler | $335 → $313 | Maintains | Overweight | |||
06/28/2024 | 102.33% | Needham | $294 → $294 | Reiterates | Buy → Buy | |||
06/27/2024 | 118.15% | RBC Capital | $317 → $317 | Reiterates | Outperform → Outperform | |||
06/26/2024 | 118.15% | RBC Capital | $317 → $317 | Reiterates | Outperform → Outperform | |||
06/05/2024 | 118.15% | RBC Capital | $317 → $317 | Reiterates | Outperform → Outperform | |||
05/29/2024 | 118.15% | RBC Capital | $317 → $317 | Reiterates | Outperform → Outperform | |||
05/23/2024 | 106.46% | HC Wainwright & Co. | $300 → $300 | Reiterates | Buy → Buy | |||
05/22/2024 | 102.33% | Needham | $294 → $294 | Reiterates | Buy → Buy | |||
05/16/2024 | 133.98% | Truist Securities | $340 → $340 | Maintains | Buy | |||
05/03/2024 | 135.36% | HSBC | $339 → $342 | Maintains | Buy | |||
04/29/2024 | 85.81% | Oppenheimer | $270 → $270 | Maintains | Outperform | |||
04/25/2024 | 102.33% | Needham | $294 → $294 | Reiterates | Buy → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Biogen (BIIB)?
El último precio objetivo de Biogen (NASDAQ:BIIB) fue comunicado por Morgan Stanley el octubre 10, 2025. La firma de analistas fijó un precio objetivo para $149.00 que espera BIIB a rise dentro de 12 meses (un posible 2.54% upside). 68 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Biogen (BIIB)?
La última calificación de analistas para Biogen (NASDAQ:BIIB) fue proporcionada por Morgan Stanley, y Biogen mantuvo su equal-weight calificación.
¿Cuándo se produjo la última revisión al alza de Biogen (BIIB)?
No hay última actualización para Biogen
¿Cuándo fue la última revisión a la baja de Biogen (BIIB)?
La última revisión a la baja de Biogen Inc se produjo en abril 4, 2025, cuando Argus Research cambió su precio objetivo de N/A a N/A para Biogen Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Biogen (BIIB)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Biogen, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Biogen se registró el octubre 10, 2025, por lo que la próxima calificación estará disponible en torno al octubre 10, 2026.
¿Es correcta la calificación de los analistas sobre Biogen (BIIB)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Biogen (BIIB) fue un mantuvo con un precio objetivo de $144.00 a $149.00. El precio actual al que cotiza Biogen (BIIB) es de $145.31, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.